Please login to the form below

Not currently logged in
Email:
Password:

PD-1 inhibitor

This page shows the latest PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Chi-Med goes for third IPO in Hong Kong

Chi-Med goes for third IPO in Hong Kong

combination with the latter’s EGFR inhibitor Tagrisso (osimertinib) and PD-L1 checkpoint inhibitor Imfinzi (durvalumab) in a series of proof-of-concept trials in solid tumours. ... It is in a clutch of trials as a monotherapy in neuroendocrine tumours

Latest news

  • Tecentriq combo shows promise in triple negative breast cancer Tecentriq combo shows promise in triple negative breast cancer

    The results of its investigational AKT-inhibitor ipatasertib added to Tecentriq and chemotherapy as a first-line treatment option demonstrated that the regimen achieved an overall response rate of 73%. ... in turn promotes immune resistance to PD-1

  • CHMP recommends new Keytruda dosing schedule CHMP recommends new Keytruda dosing schedule

    If approved by the EMA, the PD-1 inhibitor’s dosing schedule could span over six weeks at 400mg, instead of the current requirement of 200mg at every three weeks, allowing ... The PD-1/PD-L1 class is a crowded one and Keytruda’s dominance hasn’t

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    Bristol-Myers Squibb also followed a similar pattern with its PD-1 inhibitor Opdivo, after it failed in first-line NSCLC, but paired that drug up with its CTLA4 inhibitor Yervoy. ... expression and overall survival rates, casting a cloud over PD-L1

  • Innovent gears up for PD-1 inhibitor launch in China Innovent gears up for PD-1 inhibitor launch in China

    1 inhibitor Tuoyi (toripalimab) for melanoma. ... The home-grown PD-1 inhibitors join Bristol-Myers Squibb and Merck &Co/MSD’s rival drugs on the Chinese market.

  • More good news, and some bad, for Merck’s Keytruda More good news, and some bad, for Merck’s Keytruda

    It’s the second priority review filing for Keytruda to get underway at the FDA in a week, coming after the PD-1 inhibitor was filed as a first-line treatment ... The rare setback for Keytruda comes as it has started to show signs of lengthening its new

More from news
Approximately 3 fully matching, plus 198 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H). ... t the only oral JAK inhibitor developer with its eye on that particular prize.

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

  • Deal Watch January 2017 Deal Watch January 2017

    3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside USA. PRS 332 PD-1-targeting bispecific checkpoint inhibitor and 4 other candidates. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).

  • Pharma deals in September 2015 Pharma deals in September 2015

    taking rights (outside China) to a PD-1 inhibitor (POC ready) from Jaingsu Hengrui Medicine (SHR-1210) for advanced solid tumours paying a modest $25m upfront but up to $770m in ... Acquisition - company. 1, 230. Jiangsu Hengrui Medicine. Incyte.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics